RT
The startup is focused on developing a key tumor suppressor and a critical enzyme through proprietary tools that enhance rational drug design. This approach enables targeted therapeutic opportunities for patients across various cancer types and select non-oncology conditions.
Helsinki, Finland
Updated 2 months ago
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup is focused on developing a key tumor suppressor and a critical enzyme through proprietary tools that enhance rational drug design. This approach enables targeted therapeutic opportunities for patients across various cancer types and select non-oncology conditions.